Dialysis for Psoriasis - Preliminary Remarks Concerning Mode of Action

Overview

Journal Arch Dermatol Res

Specialty Dermatology

Date 1981 Jan 1

PMID 7332348

Citations 1

Authors

Z HANICKI

T Cichocki

A Klein

O Smolenski

W Sulowicz

J Czabanowska

Affiliations

Soon will be listed here.

Abstract

In one patient treated by peritoneal dialysis for psoriasis the skin lesions cleared completely. In two persons hemodialysis gave unsatisfactory results. In treated and another three untreated patients cellular immunity was evidently suppressed. This phenomenon is similar to the immunologic changes in persons with uremia. Solutes in middle molecular weight range (SMMWR) suppress cellular immunity. These compounds were therefore investigated in psoriatics. The level of SMMWR was lower before than after each dialysis, although their concentration increased slightly during the dialytic treatment. This suggests that solutes in middle molecular weight are fixed in the epidermis and/or in the walls of the skin capillaries and that dialysis liberates them from these places. Peritoneal dialysis seems to be a more effective method of treating psoriasis than hemodialysis. Solutes in middle molecular weight range might play an important role in the pathomechanisms of this multifactorial disease.

Citing Articles

New-onset psoriasis during peritoneal dialysis.

Geerse D, Suijkerbuijk J, van Poppelen K, Litjens E, Cornelis T Perit Dial Int. 2014; 34(7):802-3.

PMID: 25520486 PMC: 4269508. DOI: 10.3747/pdi.2013.00249.

References

HANICKI Z, SARNECKA-KELLER M, Klein A, Slizowska K . Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. I. Preliminary characteristics. Clin Chim Acta. 1974; 54(1):47-54. DOI: 10.1016/0009-8981(74)90041-2. View

FRANZ H, RODERMUND O . [Improvement of psoriasis by haemodialysis (author's transl)]. Dtsch Med Wochenschr. 1980; 105(26):925-8. DOI: 10.1055/s-2008-1070784. View

HANICKI Z, Cichocki T, SARNECKA-KELLER M, Klein A, Komorowska Z . Influence of middle-sized molecule aggregates from dialysate of uremic patients on lymphocyte transformation in vitro. Nephron. 1976; 17(1):73-80. DOI: 10.1159/000180713. View

TWARDOWSKI Z . [Epidermopoietin--a hypothetical psoriatogenic factor]. Przegl Dermatol. 1979; 66(1):103-8. View

Cichocki T, HANICKI Z, Klein A, Komorowska Z, SARNECKA-KELLER M, Sulowicz W . Influence of middle-molecular-weight solutes from dialysate on the migration rate of leukocytes. Kidney Int. 1980; 17(2):231-6. DOI: 10.1038/ki.1980.26. View

HANICKI Z, Cichocki T, Komorowska Z, Sulowicz W, Smolenski O . Some aspects of cellular immunity in untreated and maintenance hemodialysis patients. Nephron. 1979; 23(6):273-5. DOI: 10.1159/000181649. View

Muston H, Conceicao S . Remission of psoriasis during haemodialysis. Br Med J. 1978; 1(6111):480-1. PMC: 1603147. DOI: 10.1136/bmj.1.6111.480. View

Anderson P . Progress concerning dialysis of psoriatics. Artif Organs. 1979; 3(4):382-3. DOI: 10.1111/j.1525-1594.1979.tb01084.x. View

Glinski W, Jablonska S, Zarebska Z, Imiela J, Nosarzewski J . Continuous peritoneal dialysis for treatment of psoriasis. II. Destruction of stratum corneum with peritoneal PMNL serine proteinase. Arch Dermatol Res. 1979; 266(1):83-6. DOI: 10.1007/BF00412865. View

10.

GOMBOS E, Jefferson D, Bhat J . Effect of haemodialysis on immune response. Proc Eur Dial Transplant Assoc. 1975; 11:367-73. View

11.

Nissenson A, Rapaport M, Gordon A, Narins R . Hemodialysis in the treatment of psoriasis. A controlled trial. Ann Intern Med. 1979; 91(2):218-20. DOI: 10.7326/0003-4819-91-2-218. View

12.

Guilhou J, Meynadier J, Clot J . New concepts in the pathogenesis of psoriasis. Br J Dermatol. 1978; 98(5):585-92. DOI: 10.1111/j.1365-2133.1978.tb01949.x. View

13.

Glinski W, Haftek M, Obalek S, Jablonska S . Cell-mediated immunity (CMI) in psoriasis. Arch Immunol Ther Exp (Warsz). 1978; 26(1-6):755-60. View

14.

Twardowski Z, Nolph K, Rubin J, Anderson P . Peritoneal dialysis for psoriasis. An uncontrolled study. Ann Intern Med. 1978; 88(3):349-51. DOI: 10.7326/0003-4819-88-3-349. View

15.

Chen W, Hu C, Schiltz J, Nakamoto S . In search of "psoriasis factor(s)": a new approach by extracorporeal treatment. Artif Organs. 1978; 2(2):203-5. DOI: 10.1111/j.1525-1594.1978.tb03452.x. View

16.

McEvoy J, Kelly A . Psoriatic clearance during haemodialysis. Ulster Med J. 1976; 45(1):76-8. PMC: 2385567. View

17.

Klein A, SARNECKA-KELLER M, HANICKI Z . Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. II. Chief peptide constituents of the faction. Clin Chim Acta. 1978; 90(1):7-11. DOI: 10.1016/0009-8981(78)90077-3. View

18.

Peserico A . Development of psoriasis during dialysis. Arch Dermatol. 1979; 115(10):1169. DOI: 10.1001/archderm.115.10.1169b. View

19.

Anderson P . Dialysis for psoriasis. Artif Organs. 1978; 2(2):202. DOI: 10.1111/j.1525-1594.1978.tb03451.x. View

20.

Glinski W, Jablonska S, Imiela J, Nosarzewski J, Haftek M, Obalek S . Continuous peritoneal dialysis for treatment of psoriasis. I. Depletion of PMNL as a possible factor for clearing of psoriatic lesions. Arch Dermatol Res. 1979; 265(3):337-41. DOI: 10.1007/BF00412392. View